The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether there is a role for the selective serotonin reuptake inhibitors, fluoxetine, as therapy in the treatment of refractory primary monosymptomatic nocturnal enuresis in children , and whether there are side effects involved.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Fluoxetine

Criteria

Inclusion Criteria:

• Primary Monosymptomatic nocturnal enuresis

• Failed treatment with desmopressin.

• The enuresis alarm had either been tried without effect, or deemed unfeasible because of the family situation.

• All patients had either tried and failed combination therapy with anticholinergics or, because of contraindications, been unable to receive such therapy.

• Severe enuresis with at least seven wet nights out of 14

Exclusion Criteria:

• Underlying renal, urologic, neurologic, endocrinologic, or cardiac conditions

• Depression

• Severe psychiatric diseases

• Untreated constipation